BRAF and lung carcinoma: Thus, if the PIK3CA/BRAF prevalence in AEC is validated in a larger study, it would be reasonable to consider trials in which the AEC mutation spectrum is measured before and after treatment of lung cancer subjects bearing cancers that also have the mutation.